Achilles Therapeutics plc
ACHL · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $41,236 | $32,365 | $50,352 | $35,726 |
| - Cash | $86,052 | $95,111 | $112,322 | $131,539 |
| + Debt | $3,620 | $4,463 | $4,212 | $4,615 |
| Enterprise Value | -$41,196 | -$58,283 | -$57,758 | -$91,198 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$1,178 | -$1,179 | -$1,158 |
| % Margin | – | – | – | – |
| EBITDA | -$20,417 | -$16,622 | -$13,119 | -$18,266 |
| % Margin | – | – | – | – |
| Net Income | -$19,595 | -$16,380 | -$12,267 | -$18,792 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.48 | -0.41 | -0.3 | -0.47 |
| % Growth | -17.1% | -36.7% | 36.2% | – |
| Operating Cash Flow | – | -$17 | -$17,495 | -$14,225 |
| Capital Expenditures | – | -$0 | -$695 | -$46 |
| Free Cash Flow | – | -$17 | -$18,190 | -$14,271 |